Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOAC neoadjuvant dabrafenib/trametinib for BRAF-mutant anaplastic thyroid cancer
NL-OMON59800Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and trametinib in anaplastic thyroid cancer (ATC), sponsored by Leiden University Medical Center. Primary endpoint: Successful R0 tumor resection rate. Started Jan 2025; status: recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NL-OMON59800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59800.